Speaker(s): 

Alyssa Jones, Geisinger Ambulatory Clinical Pharmacist, Medical Therapy Disease Management - has nothing to disclose.

Scott Opalka, Geisinger Ambulatory Clinic Pharmacist, Medical Therapy Disease Managment - has nothing to disclose.

Payton Lepore, Geisinger Pharmacy Student - has nothing to disclose.

Moderator(s): 

Leonie Vachon, CRNP, Chief Nurse Practitioner Geisinger Gastroenterology Western Region - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Discuss the Approvals of Entyvio SC, Skyrizi, Omvoh, Rinvoq, and Zymfentra
• Analyze the clinical trial outcomes for the new medications and/or indications
• Review the dosing and safety of the new approvals
• Discuss Humira Biosimilars

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Karla Leschinsky, PA-C; Leonie Vachon, CRNP; Lorella Thomas, CRNP; Desiree Adams, RN and Alyssa Jones, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.